InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Opthea Corporate Presentation - April 2024 5 Apr 2024 9:34AM $0.725 $0.013 fallen by 98.21%
$18 Opteha to Participate in the 23rd Needham Virtual Conference 5 Apr 2024 9:14AM $0.725 $0.013 fallen by 98.21%
$18 Final Director's Interest Notice DS 4 Apr 2024 9:31AM $0.750 $0.013 fallen by 98.27%
$18 Initial Director's Interest Notice Sujal Shah 4 Apr 2024 9:15AM $0.750 $0.013 fallen by 98.27%
$18 Opthea Appoints Sujal Shah to the Board of Directors 4 Apr 2024 8:26AM $0.750 $0.013 fallen by 98.27%
$18 Opthea Key Opinion Leader Even on Sozinibercept 4 Apr 2024 8:20AM $0.750 $0.013 fallen by 98.27%
$18 Notification regarding unquoted securities - OPT 2 Apr 2024 12:50PM $0.758 $0.013 fallen by 98.28%
$18 Opthea to Host Key Opinion Leader Event on April 3, 2024 19 Mar 2024 11:50AM $0.630 $0.013 fallen by 97.94%
$18 Opthea to Participate in Leerink Global Biopharma Conference 6 Mar 2024 8:19AM $0.645 $0.013 fallen by 97.98%
$18 Opthea Corporate Presentation - March 2024 4 Mar 2024 11:51AM $0.635 $0.013 fallen by 97.95%
$18 Change of Director's Interest Notice Update 1 Mar 2024 10:20AM $0.675 $0.013 fallen by 98.07%
$18 Change of Director's Interest Notice 1 Mar 2024 9:52AM $0.640 $0.013 fallen by 97.97%
$18 Opthea Reports Half-Year Results and Business Update 29 Feb 2024 9:07AM $0.705 $0.013 fallen by 98.16%
$18 Half Yearly Report and Accounts 29 Feb 2024 9:06AM $0.705 $0.013 fallen by 98.16%
$18 Opthea Appoints Arshard M Khanani as Chief Medical Advisor 20 Feb 2024 9:08AM $0.630 $0.013 fallen by 97.94%
$18 Opthea Completes Enrollment in First Trial of Sozinibercept 15 Feb 2024 8:15AM $0.570 $0.013 fallen by 97.72%
$18 Opthea Strengthens Team with Key Clinical & Regulatory Hires 2 Feb 2024 8:22AM $0.480 $0.013 fallen by 97.29%
$18 Opthea to Receive US$35M Commitment and Additional US$50M 27 Dec 2023 8:28AM $0.455 $0.013 fallen by 97.14%
$18 Change of Director's Interest Notice - JL 21 Dec 2023 9:37AM $0.455 $0.013 fallen by 97.14%
$18 Change of Director's Interest Notice - LG 21 Dec 2023 9:31AM $0.455 $0.013 fallen by 97.14%
$18 Change of Director's Interest Notice - AT 21 Dec 2023 8:55AM $0.455 $0.013 fallen by 97.14%
$18 Change of Director's Interest Notice - MB 21 Dec 2023 8:54AM $0.455 $0.013 fallen by 97.14%
$18 Notification regarding unquoted securities - OPT 21 Dec 2023 8:50AM $0.455 $0.013 fallen by 97.14%
$18 Notification regarding unquoted securities - OPT 21 Dec 2023 8:49AM $0.455 $0.013 fallen by 97.14%
$18 Notification regarding unquoted securities - OPT 21 Dec 2023 8:48AM $0.455 $0.013 fallen by 97.14%

176 - 200 of 733 results

Page 8 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.